Myelodysplastic Syndromes (MDS)

ASH 2024 Update: MDS and AML

Topic(s)

Acute Myeloid Leukemia (AML)

Presenter(s)

Akriti Jain, MD

In this webinar, Dr. Akriti Jain discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and AML. These studies were presented at the American Society of Hematology (ASH) 2024 meeting and their findings will be explained along…

Bharadhwaj Kolipakkam, MD

Institution

VCU Health

Physician Status

accepting new patients

Primary Disease Area of Focus

Aplastic Anemia

Chronic Lymphocytic Leukemia (CLL)

Chronic Myelomonocytic Leukaemia (CMML)

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Read more about Bharadhwaj Kolipakkam, MD

Health Professionals as Patients with Aplastic Anemia, MDS, PNH -2026 May

Read more about Health Professionals as Patients with Aplastic Anemia, MDS, PNH -2026 May

AAMDSIF is pleased to announce that we will host a support group exclusively for Health Care Professionals diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_

MDS Virtual Support Group - Weekday - 2025 March

Read more about MDS Virtual Support Group - Weekday - 2025 March

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with MDS. The group is hosted by AAMDSIF and will be monitored to ensure the privacy and safety of our participants.

Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation

Original Publication Date

November 4, 2024

Article Source

External Web Content

It is being increasingly recognized that many patients with blood cancers harbor germline variants that increase cancer risk.1 For example, 14% of patients with acute myeloid leukemia in the BEAT AML study had germline variants associated with a hereditary hematopoietic…

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Read more about Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists

Read more about Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists

Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone

Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study

Read more about Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study

Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone

Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes

Read more about Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes

Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Read more about Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Introduction: Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez)

Subscribe to Myelodysplastic Syndromes (MDS)

Your Gift Today Changes Lives

Myelodysplastic Syndromes (MDS)

ASH 2024 Update: MDS and AML

Bharadhwaj Kolipakkam, MD

Health Professionals as Patients with Aplastic Anemia, MDS, PNH -2026 May

MDS Virtual Support Group - Weekday - 2025 March

Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists

Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study

Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Website Feedback

Patient Helpline